TGFB1 and osteogenesis imperfecta: Previously published data has suggested that direct targeting of TGFβ with the anti-mouse TGFβ antibody (1DII) also leads to reduced bone turnover and increased bone volume in the spine confirming our hypothesis that targeting this cytokine may be an effective treatment for OI (Greene et al., 2021).